Latest Prednisone Stories
NORTHBROOK, Ill., June 9 /PRNewswire/ -- Horizon Pharma, Inc., today announced that data on its two lead product candidates, LODOTRAÂ®, a circadian cytokine modulator and novel modified release, low-dose prednisone tablet, and DUEXAÂ®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, will be presented during the European League Against Rheumatism (EULAR) Annual Congress taking place in Rome, Italy, June 16-19.
PRINCETON, N.J., June 3 /PRNewswire-FirstCall/ -- Soligenix, Inc.
NORTHBROOK, Ill., May 19 /PRNewswire/ -- Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and chronic inflammation, today announced interim results from a pilot clinical study showing that LODOTRAÂ® (modified release prednisone tablet) chronotherapy may improve asthma control and asthma-related quality of life when added to standard asthma therapy in patients with severe nocturnal...
Patients with severe asthma who use an internet-supported strategy and daily monitoring of exhaled nitric oxide (FENO) were able to control their asthma with lower overall dosing of oral corticosteroids (OCS) than patients who underwent usual care.
SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
BRIDGEWATER, N.J., March 3 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.
Scientists have long struggled to understand the body's biological clock. Its tick-tock wakes us up, reminds us to eat and tells us when to go to bed. But what sets that circadian rhythm?
Minimal change nephrotic syndrome can cause osteoporosis, hypertension, cataracts and sperm abnormalities.
BASEL and REINACH, Switzerland, September 2 /PRNewswire/ -- - CAPRA-2-Data Will be Used to File for US Marketing Approval Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM). The CAPRA-2 study (Circadian Administration...
MALVERN, Pa., June 1 /PRNewswire/ -- Ascenta Therapeutics announced today that promising results from ongoing clinical studies in prostate, brain and lung cancers were among the data presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida.
- A trick or prank.